InvestorsHub Logo

dadbrotheroftwins

11/18/20 4:44 PM

#283972 RE: Jonjones325 #283968

Don't meet endpoints, no approval. No matter what you think, it's what the FDA thinks.

frrol

11/18/20 5:55 PM

#283987 RE: Jonjones325 #283968

I strongly suspect we are moving forward on PD/PDD based on this data, too. That is the lowest "good" efficacy outcome, though. Some folks sold on this, assuming by omission that we did not meet our primary efficacy endpoint. And that may not be the case, but we'll have to see. The actigraphy data is understandably voluminous and I can imagine daunting to characterize and analyze. The CDR batteries are not however and it's been 6 months, so it raises eyebrows. I can wait.